KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables (2020 - 2025)

AbCellera Biologics' Receivables history spans 6 years, with the latest figure at $71.2 million for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 127.1% year-over-year to $71.2 million, compared with a TTM value of $71.2 million through Sep 2025, up 127.1%, and an annual FY2024 reading of $33.6 million, changed N/A over the prior year.
  • Receivables for Q3 2025 was $71.2 million at AbCellera Biologics, up from $70.0 million in the prior quarter.
  • The five-year high for Receivables was $334.4 million in Q1 2022, with the low at $20.0 million in Q1 2023.
  • Average Receivables over 5 years is $78.5 million, with a median of $45.7 million recorded in 2023.
  • Year-over-year, Receivables surged 142.85% in 2022 and then plummeted 94.02% in 2023.
  • Tracing ABCL's Receivables over 5 years: stood at $160.6 million in 2021, then plummeted by 75.97% to $38.6 million in 2022, then dropped by 20.74% to $30.6 million in 2023, then rose by 9.89% to $33.6 million in 2024, then skyrocketed by 111.95% to $71.2 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Receivables are $71.2 million (Q3 2025), $70.0 million (Q2 2025), and $63.6 million (Q1 2025).